These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12412481)

  • 1. Construction and characterization of RNase-based targeted therapeutics.
    Newton DL; Futami J; Ruby D; Rybak SM
    Methods Mol Biol; 2003; 207():283-304. PubMed ID: 12412481
    [No Abstract]   [Full Text] [Related]  

  • 2. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
    Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
    Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy.
    Hombach A; Heuser C; Abken H
    Methods Mol Biol; 2003; 207():365-81. PubMed ID: 12412486
    [No Abstract]   [Full Text] [Related]  

  • 4. Generation of humanized monoclonal antibodies by 'best fit' framework selection and recombinant polymerase chain reaction.
    Lewis AP; Crowe JS
    Year Immunol; 1993; 7():110-8. PubMed ID: 8372500
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.
    Krauss J; Arndt MA; Dübel S; Rybak SM
    Curr Pharm Biotechnol; 2008 Jun; 9(3):231-4. PubMed ID: 18673289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery.
    Asai T; Wims LA; Morrison SL
    J Immunol Methods; 2005 Apr; 299(1-2):63-76. PubMed ID: 15914191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide tags for a dual affinity fusion system.
    Kim JS; Raines RT
    Anal Biochem; 1994 May; 219(1):165-6. PubMed ID: 8059949
    [No Abstract]   [Full Text] [Related]  

  • 8. Construction of single chain Fv antibody against transferrin receptor and its protein fusion with alkaline phosphatase.
    Yang DF; Zhu HF; Wang ZH; Shen GX; Tian DY
    World J Gastroenterol; 2005 Jun; 11(21):3300-3. PubMed ID: 15929188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein engineering of single-chain Fv analogs and fusion proteins.
    Huston JS; Mudgett-Hunter M; Tai MS; McCartney J; Warren F; Haber E; Oppermann H
    Methods Enzymol; 1991; 203():46-88. PubMed ID: 1762568
    [No Abstract]   [Full Text] [Related]  

  • 10. Chimerization of a monoclonal antibody for treating Hodgkin's lymphoma.
    Krauss J; Förster HH; Uchanska-Ziegler B; Ziegler A
    Methods Mol Biol; 2003; 207():63-79. PubMed ID: 12412468
    [No Abstract]   [Full Text] [Related]  

  • 11. Selection of antibodies based on antibody kinetic binding properties.
    Malmborg AC; Nilsson N; Ohlin M
    Methods Mol Biol; 2002; 178():245-53. PubMed ID: 11968494
    [No Abstract]   [Full Text] [Related]  

  • 12. The future of monoclonal antibody engineering.
    Renner C; Hartmann F; Pfreundschuh M
    Ann Hematol; 2001; 80 Suppl 3():B127-9. PubMed ID: 11757694
    [No Abstract]   [Full Text] [Related]  

  • 13. Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice.
    Newton DL; Pollock D; DiTullio P; Echelard Y; Harvey M; Wilburn B; Williams J; Hoogenboom HR; Raus JC; Meade HM; Rybak SM
    J Immunol Methods; 1999 Dec; 231(1-2):159-67. PubMed ID: 10648935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humanization of immunotoxins.
    Rybak SM; Hoogenboom HR; Meade HM; Raus JC; Schwartz D; Youle RJ
    Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3165-9. PubMed ID: 1565609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting random mutations to hotspots in antibody variable domains for affinity improvement.
    Chowdhury PS
    Methods Mol Biol; 2002; 178():269-85. PubMed ID: 11968497
    [No Abstract]   [Full Text] [Related]  

  • 16. Single-chain Fv with Fc fragment of the human IgG1 tag: construction, Pichia pastoris expression and antigen binding characterization.
    Andrade EV; Albuquerque FC; Moraes LM; Brígido MM; Santos-Silva MA
    J Biochem; 2000 Dec; 128(6):891-5. PubMed ID: 11098129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of recombinant immunotoxins for specific targeting of tumor-related peptides presented by MHC molecules.
    Cohen CJ; Denkberg G; Segal D; Reiter Y
    Methods Mol Biol; 2003; 207():269-82. PubMed ID: 12412480
    [No Abstract]   [Full Text] [Related]  

  • 18. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R
    Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
    [No Abstract]   [Full Text] [Related]  

  • 19. Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction.
    Suzuki M; Saxena SK; Boix E; Prill RJ; Vasandani VM; Ladner JE; Sung C; Youle RJ
    Nat Biotechnol; 1999 Mar; 17(3):265-70. PubMed ID: 10096294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretion of scFv antibody fragments.
    Gram H; Schmitz R; Ridder R
    Methods Mol Biol; 1998; 103():179-92. PubMed ID: 9680640
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.